img

Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application

Severe Acute Respiratory Syndrome (SARS) Therapeutics report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospital and Clinic are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Severe Acute Respiratory Syndrome (SARS) Therapeutics industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Severe Acute Respiratory Syndrome (SARS) Therapeutics key companies include CEL-SCI Corporation, GeneCure LLC, Humabs BioMed SA, Inovio Pharmaceuticals, Inc., Nanotherapeutics, Inc., Novavax, Inc., Phelix Therapeutics, LLC and Protein Sciences Corporation, etc. CEL-SCI Corporation, GeneCure LLC, Humabs BioMed SA are top 3 players and held % share in total in 2022.
Severe Acute Respiratory Syndrome (SARS) Therapeutics can be divided into CEL-1000, D-3252, FDX-000 and INO-4500, etc. CEL-1000 is the mainstream product in the market, accounting for % share globally in 2022.
Severe Acute Respiratory Syndrome (SARS) Therapeutics is widely used in various fields, such as Hospital, Clinic and Research Center,, etc. Hospital provides greatest supports to the Severe Acute Respiratory Syndrome (SARS) Therapeutics industry development. In 2022, global % share of Severe Acute Respiratory Syndrome (SARS) Therapeutics went into Hospital filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Severe Acute Respiratory Syndrome (SARS) Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report



By Company


CEL-SCI Corporation
GeneCure LLC
Humabs BioMed SA
Inovio Pharmaceuticals, Inc.
Nanotherapeutics, Inc.
Novavax, Inc.
Phelix Therapeutics, LLC
Protein Sciences Corporation
Segment by Type
CEL-1000
D-3252
FDX-000
INO-4500
LCA-60
Others

Segment by Application


Hospital
Clinic
Research Center
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries

Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia

Latin America
Mexico
Brazil

Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Severe Acute Respiratory Syndrome (SARS) Therapeutics market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Severe Acute Respiratory Syndrome (SARS) Therapeutics introduction, etc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12QYResearch’s Conclusions of Severe Acute Respiratory Syndrome (SARS) Therapeutics market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by QYResearch.

Table of Content

1 Market Overview of Severe Acute Respiratory Syndrome (SARS) Therapeutics
1.1 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Overview
1.1.1 Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Scope
1.1.2 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Status and Outlook
1.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2034
1.3 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Region (2018-2034)
1.4 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Historic Market Size by Region (2018-2024)
1.5 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Region (2024-2034)
1.6 Key Regions, Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2018-2034)
1.6.1 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2018-2034)
1.6.2 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2018-2034)
1.6.3 Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2018-2034)
1.6.4 Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2018-2034)
1.6.5 Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2018-2034)
2 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market by Type
2.1 Introduction
2.1.1 CEL-1000
2.1.2 D-3252
2.1.3 FDX-000
2.1.4 INO-4500
2.1.5 LCA-60
2.1.6 Others
2.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Type: 2018 VS 2022 VS 2034
2.2.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Historic Market Size by Type (2018-2024)
2.2.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Forecasted Market Size by Type (2024-2034)
2.3 Key Regions Market Size by Type
2.3.1 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Breakdown by Type (2018-2034)
2.3.2 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Breakdown by Type (2018-2034)
2.3.3 Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Breakdown by Type (2018-2034)
2.3.4 Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Breakdown by Type (2018-2034)
2.3.5 Middle East and Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Breakdown by Type (2018-2034)
3 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Overview by Application
3.1 Introduction
3.1.1 Hospital
3.1.2 Clinic
3.1.3 Research Center
3.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Application: 2018 VS 2022 VS 2034
3.2.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Historic Market Size by Application (2018-2024)
3.2.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Forecasted Market Size by Application (2024-2034)
3.3 Key Regions Market Size by Application
3.3.1 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Breakdown by Application (2018-2034)
3.3.2 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Breakdown by Application (2018-2034)
3.3.3 Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Breakdown by Application (2018-2034)
3.3.4 Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Breakdown by Application (2018-2034)
3.3.5 Middle East and Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Breakdown by Application (2018-2034)
4 Severe Acute Respiratory Syndrome (SARS) Therapeutics Competition Analysis by Players
4.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Players (2018-2024)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Severe Acute Respiratory Syndrome (SARS) Therapeutics as of 2022)
4.3 Date of Key Players Enter into Severe Acute Respiratory Syndrome (SARS) Therapeutics Market
4.4 Global Top Players Severe Acute Respiratory Syndrome (SARS) Therapeutics Headquarters and Area Served
4.5 Key Players Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 CEL-SCI Corporation
5.1.1 CEL-SCI Corporation Profile
5.1.2 CEL-SCI Corporation Main Business
5.1.3 CEL-SCI Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Products, Services and Solutions
5.1.4 CEL-SCI Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (US$ Million) & (2018-2024)
5.1.5 CEL-SCI Corporation Recent Developments
5.2 GeneCure LLC
5.2.1 GeneCure LLC Profile
5.2.2 GeneCure LLC Main Business
5.2.3 GeneCure LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Products, Services and Solutions
5.2.4 GeneCure LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (US$ Million) & (2018-2024)
5.2.5 GeneCure LLC Recent Developments
5.3 Humabs BioMed SA
5.3.1 Humabs BioMed SA Profile
5.3.2 Humabs BioMed SA Main Business
5.3.3 Humabs BioMed SA Severe Acute Respiratory Syndrome (SARS) Therapeutics Products, Services and Solutions
5.3.4 Humabs BioMed SA Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (US$ Million) & (2018-2024)
5.3.5 Inovio Pharmaceuticals, Inc. Recent Developments
5.4 Inovio Pharmaceuticals, Inc.
5.4.1 Inovio Pharmaceuticals, Inc. Profile
5.4.2 Inovio Pharmaceuticals, Inc. Main Business
5.4.3 Inovio Pharmaceuticals, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Products, Services and Solutions
5.4.4 Inovio Pharmaceuticals, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (US$ Million) & (2018-2024)
5.4.5 Inovio Pharmaceuticals, Inc. Recent Developments
5.5 Nanotherapeutics, Inc.
5.5.1 Nanotherapeutics, Inc. Profile
5.5.2 Nanotherapeutics, Inc. Main Business
5.5.3 Nanotherapeutics, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Products, Services and Solutions
5.5.4 Nanotherapeutics, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (US$ Million) & (2018-2024)
5.5.5 Nanotherapeutics, Inc. Recent Developments
5.6 Novavax, Inc.
5.6.1 Novavax, Inc. Profile
5.6.2 Novavax, Inc. Main Business
5.6.3 Novavax, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Products, Services and Solutions
5.6.4 Novavax, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (US$ Million) & (2018-2024)
5.6.5 Novavax, Inc. Recent Developments
5.7 Phelix Therapeutics, LLC
5.7.1 Phelix Therapeutics, LLC Profile
5.7.2 Phelix Therapeutics, LLC Main Business
5.7.3 Phelix Therapeutics, LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Products, Services and Solutions
5.7.4 Phelix Therapeutics, LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (US$ Million) & (2018-2024)
5.7.5 Phelix Therapeutics, LLC Recent Developments
5.8 Protein Sciences Corporation
5.8.1 Protein Sciences Corporation Profile
5.8.2 Protein Sciences Corporation Main Business
5.8.3 Protein Sciences Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Products, Services and Solutions
5.8.4 Protein Sciences Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (US$ Million) & (2018-2024)
5.8.5 Protein Sciences Corporation Recent Developments
6 North America
6.1 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2018-2034)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2018-2034)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Region (2018-2034)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2018-2034)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2018-2034)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Dynamics
11.1 Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Trends
11.2 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Drivers
11.3 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Challenges
11.4 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List

List of Figure

List of Tables
Table 1. Global Market Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (US$ Million) Comparison by Region 2018 VS 2022 VS 2034
Table 2. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Region (2018-2024) & (US$ Million)
Table 3. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Share by Region (2018-2024)
Table 4. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Forecasted Market Size by Region (2024-2034) & (US$ Million)
Table 5. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Forecasted Market Size Share by Region (2024-2034)
Table 6. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (US$ Million) by Type: 2018 VS 2022 VS 2034
Table 7. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Type (2018-2024) & (US$ Million)
Table 8. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share by Type (2018-2024)
Table 9. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 10. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share by Type (2024-2034)
Table 11. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Type (2018-2024) & (US$ Million)
Table 12. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Type (2024-2034) & (US$ Million)
Table 13. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Type (2018-2024) & (US$ Million)
Table 14. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Type (2024-2034) & (US$ Million)
Table 15. Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Type (2018-2024) & (US$ Million)
Table 16. Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Type (2024-2034) & (US$ Million)
Table 17. Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Type (2018-2024) & (US$ Million)
Table 18. Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Type (2024-2034) & (US$ Million)
Table 19. Middle East and Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Type (2018-2024) & (US$ Million)
Table 20. Middle East and Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Type (2024-2034) & (US$ Million)
Table 21. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (US$ Million) by Application: 2018 VS 2022 VS 2034
Table 22. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Application (2018-2024) & (US$ Million)
Table 23. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share by Application (2018-2024)
Table 24. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 25. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share by Application (2024-2034)
Table 26. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Application (2018-2024) & (US$ Million)
Table 27. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Application (2024-2034) & (US$ Million)
Table 28. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Application (2018-2024) & (US$ Million)
Table 29. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Application (2024-2034) & (US$ Million)
Table 30. Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Application (2018-2024) & (US$ Million)
Table 31. Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Application (2024-2034) & (US$ Million)
Table 32. Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Application (2018-2024) & (US$ Million)
Table 33. Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Application (2024-2034) & (US$ Million)
Table 34. Middle East and Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Application (2018-2024) & (US$ Million)
Table 35. Middle East and Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Application (2024-2034) & (US$ Million)
Table 36. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (US$ Million) by Players (2018-2024)
Table 37. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share by Players (2018-2024)
Table 38. Global Top Players Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Severe Acute Respiratory Syndrome (SARS) Therapeutics as of 2022)
Table 39. Date of Key Players Enter into Severe Acute Respiratory Syndrome (SARS) Therapeutics Market
Table 40. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Key Players Headquarters and Area Served
Table 41. Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Solution and Service
Table 42. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Players Market Concentration Ratio (CR5 and HHI)
Table 43. Mergers & Acquisitions, Expansion Plans
Table 44. CEL-SCI Corporation Basic Information List
Table 45. CEL-SCI Corporation Description and Business Overview
Table 46. CEL-SCI Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Products, Services and Solutions
Table 47. Revenue (US$ Million) in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business of CEL-SCI Corporation (2018-2024)
Table 48. CEL-SCI Corporation Recent Developments
Table 49. GeneCure LLC Basic Information List
Table 50. GeneCure LLC Description and Business Overview
Table 51. GeneCure LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Products, Services and Solutions
Table 52. Revenue (US$ Million) in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business of GeneCure LLC (2018-2024)
Table 53. GeneCure LLC Recent Developments
Table 54. Humabs BioMed SA Basic Information List
Table 55. Humabs BioMed SA Description and Business Overview
Table 56. Humabs BioMed SA Severe Acute Respiratory Syndrome (SARS) Therapeutics Products, Services and Solutions
Table 57. Revenue (US$ Million) in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business of Humabs BioMed SA (2018-2024)
Table 58. Humabs BioMed SA Recent Developments
Table 59. Inovio Pharmaceuticals, Inc. Basic Information List
Table 60. Inovio Pharmaceuticals, Inc. Description and Business Overview
Table 61. Inovio Pharmaceuticals, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Products, Services and Solutions
Table 62. Revenue (US$ Million) in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business of Inovio Pharmaceuticals, Inc. (2018-2024)
Table 63. Inovio Pharmaceuticals, Inc. Recent Developments
Table 64. Nanotherapeutics, Inc. Basic Information List
Table 65. Nanotherapeutics, Inc. Description and Business Overview
Table 66. Nanotherapeutics, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Products, Services and Solutions
Table 67. Revenue (US$ Million) in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business of Nanotherapeutics, Inc. (2018-2024)
Table 68. Nanotherapeutics, Inc. Recent Developments
Table 69. Novavax, Inc. Basic Information List
Table 70. Novavax, Inc. Description and Business Overview
Table 71. Novavax, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Products, Services and Solutions
Table 72. Revenue (US$ Million) in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business of Novavax, Inc. (2018-2024)
Table 73. Novavax, Inc. Recent Developments
Table 74. Phelix Therapeutics, LLC Basic Information List
Table 75. Phelix Therapeutics, LLC Description and Business Overview
Table 76. Phelix Therapeutics, LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Products, Services and Solutions
Table 77. Revenue (US$ Million) in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business of Phelix Therapeutics, LLC (2018-2024)
Table 78. Phelix Therapeutics, LLC Recent Developments
Table 79. Protein Sciences Corporation Basic Information List
Table 80. Protein Sciences Corporation Description and Business Overview
Table 81. Protein Sciences Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Products, Services and Solutions
Table 82. Revenue (US$ Million) in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business of Protein Sciences Corporation (2018-2024)
Table 83. Protein Sciences Corporation Recent Developments
Table 84. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2018-2024) & (US$ Million)
Table 85. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2024-2034) & (US$ Million)
Table 86. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2018-2024) & (US$ Million)
Table 87. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2024-2034) & (US$ Million)
Table 88. Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2034
Table 89. Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Region (2018-2024) & (US$ Million)
Table 90. Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Region (2024-2034) & (US$ Million)
Table 91. Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Region (2018-2024)
Table 92. Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Region (2024-2034)
Table 93. Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2034
Table 94. Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2018-2024) & (US$ Million)
Table 95. Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2024-2034) & (US$ Million)
Table 96. Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2034
Table 97. Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2018-2024) & (US$ Million)
Table 98. Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2024-2034) & (US$ Million)
Table 99. Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Trends
Table 100. Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Drivers
Table 101. Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Challenges
Table 102. Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Restraints
Table 103. Research Programs/Design for This Report
Table 104. Key Data Information from Secondary Sources
Table 105. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Year-over-Year 2018-2034 & (US$ Million)
Figure 2. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (US$ Million), 2018 VS 2022 VS 2034
Figure 3. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Regions: 2022 VS 2034
Figure 4. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Forecasted Market Size Share by Region (2024-2034)
Figure 5. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate (2018-2034) & (US$ Million)
Figure 6. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate (2018-2034) & (US$ Million)
Figure 7. Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate (2018-2034) & (US$ Million)
Figure 8. Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate (2018-2034) & (US$ Million)
Figure 9. Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate (2018-2034) & (US$ Million)
Figure 10. Product Picture of CEL-1000
Figure 11. Global CEL-1000 Market Size (US$ Million) & YoY Growth (2018-2034)
Figure 12. Product Picture of D-3252
Figure 13. Global D-3252 Market Size (US$ Million) & YoY Growth (2018-2034)
Figure 14. Product Picture of FDX-000
Figure 15. Global FDX-000 Market Size (US$ Million) & YoY Growth (2018-2034)
Figure 16. Product Picture of INO-4500
Figure 17. Global INO-4500 Market Size (US$ Million) & YoY Growth (2018-2034)
Figure 18. Product Picture of LCA-60
Figure 19. Global LCA-60 Market Size (US$ Million) & YoY Growth (2018-2034)
Figure 20. Product Picture of Others
Figure 21. Global Others Market Size (US$ Million) & YoY Growth (2018-2034)
Figure 22. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Share by Type: 2022 & 2034
Figure 23. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share by Type (2018-2034)
Figure 24. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share by Type (2018-2034)
Figure 25. Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share by Type (2018-2034)
Figure 26. Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share by Type (2018-2034)
Figure 27. Middle East and Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share by Type (2018-2034)
Figure 28. Hospital Market Size (US$ Million) & YoY Growth (2018-2034)
Figure 29. Clinic Market Size (US$ Million) & YoY Growth (2018-2034)
Figure 30. Research Center Market Size (US$ Million) & YoY Growth (2018-2034)
Figure 31. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Share by Application: 2022 & 2034
Figure 32. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share by Application (2018-2034)
Figure 33. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share by Application (2018-2034)
Figure 34. Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share by Application (2018-2034)
Figure 35. Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share by Application (2018-2034)
Figure 36. Middle East and Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share by Application (2018-2034)
Figure 37. Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 38. Global Top 5 and Top 10 Players Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share in 2022
Figure 39. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Country (2018-2034)
Figure 40. U.S. Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2018-2034) & (US$ Million)
Figure 41. Canada Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2018-2034) & (US$ Million)
Figure 42. Germany Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2018-2034) & (US$ Million)
Figure 43. France Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2018-2034) & (US$ Million)
Figure 44. U.K. Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2018-2034) & (US$ Million)
Figure 45. Italy Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2018-2034) & (US$ Million)
Figure 46. Russia Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2018-2034) & (US$ Million)
Figure 47. Nordic Countries Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2018-2034) & (US$ Million)
Figure 48. Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Region (2018-2034)
Figure 49. China Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2018-2034) & (US$ Million)
Figure 50. Japan Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2018-2034) & (US$ Million)
Figure 51. South Korea Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2018-2034) & (US$ Million)
Figure 52. Southeast Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2018-2034) & (US$ Million)
Figure 53. India Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2018-2034) & (US$ Million)
Figure 54. Australia Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2018-2034) & (US$ Million)
Figure 55. Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Country (2018-2034)
Figure 56. Mexico Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2018-2034) & (US$ Million)
Figure 57. Brazil Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2018-2034) & (US$ Million)
Figure 58. Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Country (2018-2034)
Figure 59. Turkey Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2018-2034) & (US$ Million)
Figure 60. Saudi Arabia Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2018-2034) & (US$ Million)
Figure 61. UAE Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2018-2034) & (US$ Million)
Figure 62. Bottom-up and Top-down Approaches for This Report

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries